pharmaceuticals

Hyperion acquires Andromeda for up to $570m

The Clal Biotechnology subsidiary is in a Phase III clinical trial for a Type 1 diabetes treatment.

BusinessWire
Twitter Facebook Linkedin RSS Newsletters